Scarica l'app Stockscreener
6.47
0.47%
0.03
Dopo l'orario di chiusura:
6.50
0.03
+0.46%
Precedente Chiudi:
$6.44
Aprire:
$6.42
Volume 24 ore:
1.08M
Relative Volume:
0.87
Capitalizzazione di mercato:
$560.14M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-2.9816
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
-1.97%
1M Prestazione:
+8.19%
6M Prestazione:
-18.92%
1 anno Prestazione:
-68.22%
Intervallo 1D:
$6.40
$6.555
Intervallo di 1 settimana:
$6.255
$6.69
Portata 52W:
$5.41
$21.60
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
6.47 | 557.54M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Is Kura Oncology Inc. a good long term investmentFree Real-Time Stock Data - Autocar Professional
Will Kura Oncology Inc. stock benefit from interest rate changesFree Stock Chart Pattern Guide - jammulinksnews.com
Can Kura Oncology Inc. stock recover from recent declineFree Predictions - jammulinksnews.com
What analysts say about Kura Oncology Inc. stockExplosive returns - Autocar Professional
What drives Kura Oncology Inc. stock priceAccelerated wealth building - jammulinksnews.com
Kura Oncology Inc. Stock Analysis and ForecastExplosive earnings growth - jammulinksnews.com
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Why Kura Oncology Inc. stock attracts strong analyst attentionFree AI-Driven Trading Strategies - Newser
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - Yahoo Finance
How Kura Oncology Inc. stock performs during market volatilityFree Access to Group - Newser
What makes Kura Oncology Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt? - simplywall.st
Wealth Enhancement Advisory Services LLC Takes $139,000 Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology shares rise 3.34% after-hours following inducement grants to new employees. - AInvest
Kura Oncology's Ziftomenib: A Near-Term FDA Catalyst and a Paradigm Shift for AML Patients - AInvest
Kura Oncology Partners with Kyowa Kirin for Ziftomenib - TipRanks
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.com
Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US By Investing.com - Investing.com South Africa
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 3000E Value Index - MarketScreener
Kura Oncology (NASDAQ:KURA) Given Overweight Rating at Cantor Fitzgerald - Defense World
KURA: Cantor Fitzgerald Reiterates Overweight Rating | KURA Stoc - GuruFocus
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Rhumbline Advisers - Defense World
KURA: Wedbush Reiterates 'Outperform' Rating with $36 Price Target | KURA Stock News - GuruFocus
Transcript : Kura Oncology, Inc.Special Call - MarketScreener
Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks
Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Australia
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):